FDA Approval: 1L Durvalumab + Tremelimumab + Chemotherapy for NSCLC

Dr. Narjust Florez discusses the POSEIDON trial with guest Dr. Tejas Patil, assistant professor at Thoracic Oncology Research Initiative, University of Colorado Cancer Center. This Phase III study led to the recent FDA approval of Tremelimumab in combination with Durvalumab and chemotherapy as first-line treatment in patients with metastatic non small-cell lung cancer (NSCLC).